Gurobi Helps Software Companies Successfully Integrate Optimization Into Their Solutions
15.9.2022 03:50:00 EEST | Business Wire | Press release
Gurobi Optimization, LLC, creator of the world’s fastest mathematical optimization solver, has launched a new program to help independent software vendors (ISVs) tackle customers’ increasingly complex business challenges and keep up with ever-evolving customer needs.
While 85% of Fortune 500 companies use mathematical optimization, smaller startups and scaleups in the tech world are catching on to the value an industry-leading solver like Gurobi can bring to their software solutions. In fact, 70% of top global tech companies now use Gurobi.
Gurobi wants to be more than just a supplier to the ISVs that utilize its mathematical optimization technology; it wants to be a partner. That is the motivation behind the new Gurobi Partner Accelerator Program.
The 36-month program aims to create joint value between Gurobi and solution providers by setting and achieving shared business, product, and revenue goals.
“It’s not just a supplier relationship. We see it as a partnership. We want to support these companies and go hand-in-hand with them. If they grow, we grow together,” explained Jan Schwarzkopf, Gurobi Account Manager - Europe Ecosystem.
The Gurobi Partner Accelerator Program
Gurobi is offering a partnership with companies in the final stages of developing a software solution that utilizes its optimization technology. Companies will receive ongoing technical support, which is a critical asset in these final development stages.
In addition to technical support, partner companies will receive business and marketing support to accelerate their product’s time to market and maximize sales once launched.
This program is not just for companies in the development stage, though. ISVs that utilize Gurobi for products already on the market will also be eligible. The program’s ongoing technical and business support is essential for any company that wants to enhance its product to stay ahead in the highly competitive software market.
Benefits of the Program
By participating in the program, ISVs will receive the following:
- Easy Access to Gurobi’s Technology - Solution partners will receive access to Gurobi’s best-in-class technology, including a product license based on their business needs.
- Ongoing Sales and Marketing Support - The program includes guidance on sales and marketing strategies. Gurobi will work hand-in-hand with partners to advise on the best way to market their product and maximize sales once launched.
- Quarterly Engagement for Business Strategy - Gurobi will meet at least quarterly with solution partners to assist with high-level business strategy. Partners will get expert guidance on formulating and executing business goals.
Who Should Consider This Program?
The Gurobi Partner Accelerator Program is not limited to ISVs currently using Gurobi’s technology for their software solutions. Companies using an open-source solver or competitive commercial solver are also encouraged to consider the program.
For those using either an open-source or commercial solver, Gurobi poses the following questions:
- Are you or your end customers satisfied with the current performance of your software application?
- Does your relationship with your current optimization technology supplier support your business growth?
If the answer to one or both of these questions is no, the Gurobi Partner Accelerator Program might be the solution.
The software industry is getting more competitive every year, and ISVs need to ensure their solutions use every advantage available. The Gurobi Partner Accelerator Program is an excellent opportunity to access leading optimization solver technology, as well as hands-on support from experts who want their partners to succeed with optimization.
To learn more about the program, please visit https://www.gurobi.com/gurobi-alliance/gurobi-partner-accelerator-program/.
About Gurobi Optimization
With Gurobi’s decision intelligence technology, you can make optimal business decisions in seconds. From workforce scheduling, portfolio management, and marketing optimization, to supply chain design, and everything in between, Gurobi identifies your optimal solution, out of trillions of possibilities.
As the leader in decision intelligence, Gurobi delivers easy-to-integrate, full-featured software and best-in-class support, with an industry-leading 98.5% customer satisfaction rating.
Founded in 2008, Gurobi has operations across the Americas, Europe, and Asia. Over 2,500 global customers across 40+ industries run on Gurobi, including SAP, Air France, and the National Football League, as well as half of the Fortune 10 and 70% of top global tech companies. For more information, please visit https://www.gurobi.com/ or call +1 713 871 9341.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220901005558/en/
Contact information
Nell-Marie Colman
(540) 952 9719
Gurobi Optimization
colman@gurobi.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom